VRTX vs ZBH
Vertex Pharmaceuticals vs Zimmer Biomet — AI-powered side-by-side comparison
VRTX
Vertex Pharmaceuticals
67
Buy
VS
| Metric | VRTX | ZBH |
|---|
| AI Score |
67
|
70
|
| Price |
$496.21
|
$96.61
|
| P/E Ratio |
28.64×
|
23.38×
|
| ROE |
21.2%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
86.0%
|
69.9%
|
| Debt / Equity |
0.00×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
66.6
|
58.9
|
| Beta |
0.292
|
0.468
|
| Expected Upside |
+2.3%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for VRTX versus ZBH.
ZBH leads by 3 points.
ZBH scores 70/100 (Buy) versus VRTX at 67/100 (Buy).
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 28.3 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 28.3 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.